Middle East and Africa Viral Vectors and Plasmid DNA Manufacturing Market (By Vector Type: Adenovirus, Retrovirus, Adeno-Associated Virus (AAV), Lentivirus, Plasmids, Others; By Workflow: Upstream Manufacturing (Vector Amplification & Expansion, Vector Recovery/Harvesting), Downstream Manufacturing (Purification, Fill Finish); By Application Outlook: Antisense & RNAi Therapy, Gene Therapy, Cell Therapy, Vaccinology, Research Applications; By End-use Outlook: Pharmaceutical and Biopharmaceutical Companies, Research Institutes; By Disease Outlook: Cancer, Genetic Disorders, Infectious Diseases, Others) Industry Size, Share, Growth, Trends 2026 to 2035
The Middle East & Africa viral vectors and plasmid DNA manufacturing market was valued at USD 141.51 million in 2025 and is forecast to reach USD 420.39 million by 2035, expanding at an 11.50% CAGR driven by growing gene therapy adoption and biotech investments.
| Reports Attributes | Statistics |
| Market Size in 2025 | USD 141.51 Million |
| Market Size in 2026 | USD 158.07 Million |
| Market Size in 2032 | USD 307.02 Million |
| Market Size by 2035 | USD 420.39 Million |
| CAGR 2026 to 2035 | 11.50% |
| Base Year | 2025 |
| Forecast Period | 2026 to 2035 |
The Middle East and Africa viral vectors and plasmid DNA manufacturing is gaining momentum due to the increasing government funding towards improvement of local biomanufacturing that reduces the reliance on other countries for vaccines and other biologics. As a result, there has been an increasing focus on promoting AAV, lentivirus, adenovirus, and many more, which can be used in gene therapies and DNA-based vaccines. The region has been constantly advancing in its infrastructure, which also attracts huge focus on healthcare, which can conduct clinical research activities. The leading countries are trying to invest in life sciences parks and other projects to attract more advancements in biologics.
The Middle East and Africa viral vectors and plasmid DNA manufacturing market is in its initial years, and has gained significant attention in healthcare research. However, the region struggles with the import cost of chromatography resins, sterile filters, and other consumables, which can add up to the overall costs. Except for some leading countries like the UAE and Saudi Arabia, other countries in the region still have a limited number of professional experts, which can create challenges in the growth pace.
The growing improvement pace of healthcare services in the MEA region is driven by research for vaccines and therapeutics. The clinical facilities are heavily driven by the increasing flow of modular facilities like single-use GMP suites, which can be helpful in the long run for the emerging countries in the region. The government is investing in public and private partnerships that can open the doors for foreign investors to help in manufacturing materials that can be used in gene therapies and vaccines. The technological improvements, like analytics and QC services, are also helping the companies to improve their accuracy and time in these processes. Additionally, the focus on training and academics will also help the companies to improve the manufacturing base in the coming years.
The contribution of artificial intelligence and machine learning has been marking crucial growth in design and development, where AI can screen new capsid variants and optimize for more safety. These models are also helping the developers to predict incomplete viral genomes. Many companies are implementing AI for higher yields, where it analyzes large datasets to find patterns for the same. The prediction capability of AI is also maintaining the quality by predicting the genotoxicity of vectors. The regulatory burden also decreases by using NLP and RPA batch records that keep a detailed analysis, which further helps the Middle East and Africa viral vectors and plasmid DNA manufacturing market to grow.
Saudi Arabia stands as a crucial player in the market due to their several investments in biotech and life science projects through dedicated innovation of research labs. The primary aim of the government is to improve the healthcare sector by deploying technologies and equipment for therapeutics, which promotes material innovation. The futuristic approach of Saudi Arabia in partnering with global CDMOs and equipment manufacturers is expected to attract more revenue in the future.
The United Arab Emirates is one of the fastest-growing countries in the region in terms of healthcare improvements. The government is highly adopting an ecosystem-like science. park, which will drive the future of biotech manufacturing in the future. The country aims to improve the base for GMP-certified facilities in the future that mark advancements by maintaining the regulatory norms and standards.
| Segments | Shares (%) |
| Adenovirus | 20.16% |
| Retrovirus | 11.43% |
| Adeno-Associated Virus (AAV) | 22.37% |
| Lentivirus | 18.17% |
| Plasmids | 2.45% |
| Others | 25.42% |
| Segments | Shares (%) |
| Upstream Manufacturing | 64.79% |
| Downstream Manufacturing | 35.21% |
| Segments | Shares (%) |
| Antisense & RNAi Therapy | 4.44% |
| Gene Therapy | 27.45% |
| Cell Therapy | 11.48% |
| Vaccinology | 26.93% |
| Research Applications | 29.69% |
| Segments | Shares (%) |
| Pharmaceutical and Biopharmaceutical Companies | 24.35% |
| Research Institutes | 75.65% |
| Segments | Shares (%) |
| Cancer | 29.53% |
| Genetic Disorders | 13.12% |
| Infectious Diseases | 19.82% |
| Others | 37.53% |
Published by Ajit Bansod
